Pacira BioSciences, Inc. (PCRX)

NASDAQ: PCRX · IEX Real-Time Price · USD
30.68
-0.17 (-0.55%)
Sep 29, 2023, 4:00 PM EDT - Market closed
-0.55%
Market Cap 1.52B
Revenue (ttm) 669.23M
Net Income (ttm) -4.57M
Shares Out 49.65M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE 8.57
Dividend n/a
Ex-Dividend Date n/a
Volume 738,365
Open 31.12
Previous Close 30.85
Day's Range 30.43 - 31.12
52-Week Range 30.43 - 58.10
Beta 0.70
Analysts Strong Buy
Price Target 57.33 (+86.86%)
Earnings Date Nov 2, 2023

About PCRX

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsula... [Read more]

Sector Healthcare
IPO Date Feb 3, 2011
Employees 715
Stock Exchange NASDAQ
Ticker Symbol PCRX
Full Company Profile

Financial Performance

In 2022, PCRX's revenue was $666.82 million, an increase of 23.14% compared to the previous year's $541.53 million. Earnings were $15.91 million, a decrease of -62.10%.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price forecast is $57.33, which is an increase of 86.86% from the latest price.

Price Target
$57.33
(86.86% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Pacira BioSciences Announces Leadership Succession Plan

David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor TAMPA, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), ...

4 days ago - GlobeNewsWire

Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference

TAMPA, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Inve...

25 days ago - GlobeNewsWire

Pacira BioSciences Reports Second Quarter 2023 Financial Results

-- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management ...

2 months ago - GlobeNewsWire

Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference

TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 RBC Capital Markets Global He...

5 months ago - GlobeNewsWire

Pacira BioSciences Reports First Quarter 2023 Financial Results

-- EXPAREL continues to outperform elective surgery market with average daily volumes up 6 percent over prior year -- -- Conference call today at 8:30 a.m. ET --

5 months ago - GlobeNewsWire

Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023

TAMPA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on We...

5 months ago - GlobeNewsWire

Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer

TAMPA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today an...

5 months ago - GlobeNewsWire

Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

TAMPA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 22nd Annual Needham Virtual Heal...

6 months ago - GlobeNewsWire

Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit

TAMPA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that the United States Court of Appeals for the Third Circuit affirmed the District Court's dism...

6 months ago - GlobeNewsWire

Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors

TAMPA, Fla., March 22, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today an...

6 months ago - GlobeNewsWire

Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference

TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Confe...

7 months ago - GlobeNewsWire

Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results

— Record revenues of $667 million in 2022 —

7 months ago - GlobeNewsWire

Pacira to Report 2022 Financial Results on Tuesday February 28, 2023

TAMPA, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2022 financial results before t...

7 months ago - GlobeNewsWire

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million

EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December EXPAREL average daily sales 104% of the prior year for the fourth quarter...

9 months ago - GlobeNewsWire

Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference at 3:00 PM PT (6:00PM E...

9 months ago - GlobeNewsWire

Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022

-- EXPAREL average daily sales for October 2022 were 106 percent of October 2021 -- TAMPA, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its c...

11 months ago - GlobeNewsWire

Pacira BioSciences to Present at Two Healthcare Conferences in November

TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferen...

11 months ago - GlobeNewsWire

Pacira BioSciences Reports Third Quarter 2022 Financial Results

-- Third quarter revenue of $167 million , increased 31% over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq:...

11 months ago - GlobeNewsWire

Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022

TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thu...

1 year ago - GlobeNewsWire

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- -- Compa...

1 year ago - GlobeNewsWire

Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

-- European Commission decision on the Marketing Authorization Application (MAA) expected in November 2022 -- -- European Commission decision on the Marketing Authorization Application (MAA) expected ...

1 year ago - GlobeNewsWire

Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022

-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 –

1 year ago - GlobeNewsWire

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Study achieved primary and key secondary endpoints of statistically significant reductions in postsurgical pain and opioid consumption through 96 hours Study achieved primary and key secondary endpoin...

1 year ago - GlobeNewsWire

Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022

-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 -- TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitm...

1 year ago - GlobeNewsWire

NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communities About Non-Opioid Options to Manage Pain

-- Multi-year initiative will leverage NFL Alumni events and educational opportunities to raise awareness about effective opioid alternatives -- -- Multi-year initiative will leverage NFL Alumni event...

1 year ago - GlobeNewsWire